Identification of New FLT3 Inhibitors That Potently Inhibit AML Cell Lines via an Azo Click-It/Staple-It Approach
Xiaochu Ma, Jie Zhou, Changhao Wang, Brandon Carter-Cooper, Fan Yang, Elizabeth Larocqu, Jonathan Fine, Genichiro Tsuji, Gaurav Chopra, Rena G. Lapidus, and Herman O. Sintim
Dual FLT3/TOPK inhibitor with activity against FLT3-ITD secondary mutations potently inhibits acute myeloid leukemia cell lines
Neetu Daya, Clement Opoku-Temeng, Delmis E Hernandez, Moloud Aflaki Sooreshjani, Brandon A Carter-Cooper, Rena G Lapidus, Herman O Sintim
Alkynylnicotinamide-based compounds as ABL1 inhibitors with potent activities against drug-resistant CML harboring ABL1(T315I) mutant kinase
Elizabeth A. Larocque, Dr. N Naganna, Clement Opoku-Temeng, Alyssa M. Lambrecht, and Prof. Dr. Herman O. Sintim
KRX-101, a novel FLT3 inhibitor, potently active against resistant FLT3-ITD/FLT3-TKD mutant AML in vitro and in vivo
Herman O Sintim, M. Javad Aman, Frederick Holtsberg, Ashkan Emadi and Rena G Lapidus. Blood, 2018, 132:4049; doi: 10.1182/blood-2018-99-115260
Amino alkynylisoquinoline and alkynylnaphthyridine compounds potently inhibit acute myeloid leukemia proliferation in mice
Naganna N, Opoku-Temeng C, Choi EY, Larocque E, Chang ET, Lapidus RG, Sintim HO. EBioMedicine, 2019, 40, p. 231-239 doi: 10.1016/j.ebiom.2019.01.012
Nicotinamide–Ponatinib Analogues as Potent Anti-CML and Anti-AML Compounds
Larocque, E.; Chu, E. F. Y.; Naganna, N.; Sintim, H. O. ACS Omega 2020, 5, 6, 2690–2698.